| NIPPON ZOKI PHARMACEUTICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135083 | DRIED PRODUCT AND A PROCESS FOR MANUFACTURING THE PRODUCT - A dried product of an extract from inflammatory rabbit skin inoculated with vaccinia virus having an inhibitory activity for the production of a kallikrein-like substance is produced by admixing the extract with a saccharide, sugar alcohol or ascorbic acid before reaching dryness, and then drying the admixture to a solid form such as granules. The dried product may be employed to produce a solid preparation for oral administration, such as tablets, having an inhibitory activity for the production of a kallikrein-like substance. | 05-31-2012 |
| 20120123127 | PROCESS FOR PRODUCING THIABENZOAZULENE-PROPIONIC ACID DERIVATIVE - Disclosed is a process for producing a thiabenzoazulene-propionic acid derivative which is useful as an active ingredient of an antihistaminic agent or the like. According to the producing process of the present invention, it is possible to produce a thiabenzoazulene-propionic acid derivative where the 2-position of the thiabenzoazulene skeleton is substituted with propionic acid. The thiabenzoazulene propionic-acid derivative thus synthesized has excellent antagonistic action to histamine H1 receptor and low intracerebral transmigration and, therefore, is useful as an active ingredient of the pharmaceutical composition such as an antihistaminic agent. | 05-17-2012 |
| 20110172442 | AMINO ACID DERIVATIVE - The amino acid derivative of the present invention provides a novel compound that shows excellent analgesic action. The amino acid derivative of the present invention is a novel compound that shows excellent analgesic action to not only a model animal for nociceptive pains but also a model animal for neuropathic pains, so that the amino acid derivative is very useful as a drug for treating various pain diseases. | 07-14-2011 |
| 20110160434 | FIBROMYALGIA TEST METHOD - A method for diagnosing or testing for fibromyalgia with a specific peptide in the blood as an indicator, as well as a method for effectively evaluating or assessing a fibromyalgia drug with the peptide as an indicator. A method for diagnosing or testing for fibromyalgia or for evaluating or assessing a fibromyalgia drug, by subjecting a patient's serum to peptide analysis using as an indicator (biomarker) a peptide that demonstrates a specific expression amount in the blood of a fibromyalgia patient. | 06-30-2011 |
| 20110151001 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING PROCHLORPERAZINE - Disclosed is a novel pharmaceutical composition for external application for increasing the permeation of prochlorperazine or a pharmaceutically acceptable salt thereof through the skin to allow prochlorperazine or the pharmaceutically acceptable salt thereof to exhibit its excellent pharmacological activity. Specifically disclosed is a novel pharmaceutical composition for external application, which contains prochlorperazine or a pharmaceutically acceptable salt thereof as an active ingredient and further contains menthol. The composition contains, as an active ingredient, prochlorperazine which has been widely used clinically as the first-line drug of a therapeutic agent for nausea or vomiting before or after a surgery or the like, and is extremely highly useful as a transdermally absorbable antiemetic agent that has excellent efficacy and can be used safely over a long period. | 06-23-2011 |
| 20110124856 | AMINOPROPYLIDENE DERIVATIVE - An aminopropylidene derivative having excellent histamine receptor antagonistic action, a compound which is useful as a pharmaceutical composition, especially as an active ingredient, having alleviated side effects in the central nervous system is described. In the aminopropylidene derivative, R | 05-26-2011 |
| 20110111051 | PROPHYLACTIC OR ALLEVIATING AGENT FOR PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENT - There is provided a medicinal agent that is effective and highly safe for the prevention or alleviation of a peripheral nerve disorder that develops as a side effect occurring after the administration of an anti-cancer agent. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and to a prophylactic or alleviating agent for a peripheral nerve disorder that contains the extract as an active ingredient. The agent containing the extract as an active ingredient is used for a prophylactic or alleviating agent for a peripheral nerve disorder induced by an anti-cancer agent and is a highly safe and remarkably highly useful medicinal agent with few side effects. | 05-12-2011 |
| 20110031157 | PLASTIC AMPULE - A plastic ampule comprising a body portion, a head portion provided continuously to the mouth portion of the body portion through a cut-off portion, and a knob portion provided continuously to the head portion the ampule being unsealed by twisting the knob portion with fingers to cut the head portion off the mouth portion, wherein the hollow portion in the head portion is formed in the shape of a bowl. Since the hollow portion is formed in the shape of a bowl, content liquid remaining in the hollow portion can be discharged easily, the plastic ampule can be unsealed easily, and the content liquid remaining in the hollow portion is not scattered easily at the time of unsealing. | 02-10-2011 |
| 20100331365 | PIPERIDINE DERIVATIVE - The present invention provides a compound a piperidine derivative having excellent histamine receptor antagonistic action, which is useful as active ingredients of a pharmaceutical composition, especially an antihistamine. The piperidine derivative of the present invention has a potent histamine receptor antagonistic action. Further, the compound of the present invention shows low brain transfer even in a cerebral receptor binding test where a mouse is orally administered with the compound, so that the compound has preferred properties of alleviating side effects in the central nervous system, such as drowsiness. The piperidine derivative of the present invention is very useful as a novel antihistamine having smaller side effects in the central nervous system, such as drowsiness. | 12-30-2010 |
| 20100152459 | NOVEL HISTIDINE DERIVATIVES - The present invention is to provide a novel compound which is useful as a pharmaceutical agent such as an analgesic. The present invention is to provide the novel histidine derivative having an excellent analgesic action and the like. The compound of the present invention has a very high intermigration into the blood upon oral administration and is very useful as a pharmaceutical agent, especially an analgesic for the treatment of acute or chronic pain diseases and of neuropathic pain diseases. | 06-17-2010 |
| 20100121040 | THERAPEUTIC AGENT FOR PAIN DISEASE - Disclosed is an analgesic agent for a non-inflammatory pain disease, which comprises a sialic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The sialic acid which is an active ingredient for the agent has an analgesic effect on a disease model animal of neurogenic pain which is a non-inflammatory pain. Therefore, the analgesic agent is useful as a pharmaceutical agent for the treatment of a non-inflammatory pain disease such as a neurogenic pain disease, e.g. trigeminal neuralgia, postherpetic neuralgia, entrapment neuropathy, complex regional pain syndrome, diabetic neuropathy, traumatic neuropathy, phantom limb pain, central pain after spinal cord injury or stroke, and neuropathy caused by pharmacotherapy or radiation therapy, or the like. | 05-13-2010 |
| 20100048408 | Method for study, determination or evaluation by gene expression analysis - There is provided a method for study, determination or evaluation of a disease condition due to SART stressing or a pharmacological activity, for example an analgesic activity, an autonomic imbalance-ameliorating activity or an anti-stress activity, of a test substance at the gene level. It is a method for study, determination or evaluation of a pharmacological activity of a test substance, especially an analgesic activity, an autonomic imbalance-ameliorating activity, or an anti-stress activity at the gene level by comprehensively analyzing the change in gene expression in a neural tissue after administration of a test substance in a SART-stressed animal. The method enables exploration of the substance that is effective against painful diseases, stress-related diseases, autonomic-imbalance or the like, determination and evaluation of efficacy of the substance, or analysis of a target gene of the substance | 02-25-2010 |
| 20100021431 | Agent for Promoting the Production of Thioredoxin - A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety. | 01-28-2010 |
| 20100004459 | 2-PHENYLNICOTINIC ACID DERIVATIVE - The present invention is to provide the compounds useful as a treating or preventing agent for gout and hyperuricemia which are 2-phenylnicotinic acid derivatives having a uric acid lowering action due to an excellent xanthine oxidase inhibitory action. Since the 2-phenylnicotinic acid derivatives of the present invention exhibit a uric acid lowering action due to an excellent xanthine oxidase inhibitory action and also hypolipemic action, their utility is very high as a treating or preventive agent for gout and hyperuricemia which are often accompanied by hyperlipemia as a complication. | 01-07-2010 |
| 20090272649 | Method for study, determination or evaluation - A method for studying, determining or evaluating a pharmacological action of a test substance, the method including subjecting the brain tissue of an SART stressed animal administered with the test substance to an expression proteome analysis, where expression changes of NSF (N-ethylmaleimide sensitive fusion protein), which is or is not modified after translation, in the SART stressed animal administered with the test substance as compared with an SART stressed animal to which a test substance is not administered is used as an index. | 11-05-2009 |
| 20090270634 | NOVEL CRYSTAL FORM OF 5-HYDROXY-1-METHYLHYDANTOIN - Conventional I-form crystals of 5-hydroxy-1-methylhydantoin contain, remaining therein in a considerable amount, the organic solvent used in a purification step. In contrast, in II-form crystals, the amount of the organic solvent remaining therein is smaller than the detection limit. Namely, the II-form crystals contain substantially no residual organic solvent. The novel II-form crystals of 5-hydroxy-1-methylhydantoin obtained through recrystallization from water not only contain substantially no residual organic solvent, but also have a high bulk density and are hence advantageous for pharmaceutical preparation. They further have properties advantageous for production, such as low adhesion. The crystals are significantly useful as a material for medicines required to have high safety, such as drugs for renal insufficiency. | 10-29-2009 |
| 20090149658 | Novel Histidine Derivatives - The present invention is to provide a novel compound which is useful as an excellent analgesic agent. The present invention is to provide the novel histidine derivative having an excellent analgesic action and the like. The compound of the present invention is very useful as a pharmaceutical agent such as analgesics for the treatment of various kinds of acute or chronic pain diseases and of neuropathic pain diseases. | 06-11-2009 |
| 20080262230 | Benzyloxypropylamine Derivative - Disclosed is a novel benzyloxypropylamine derivative having an excellent tachykinin receptor antagonistic effect. This compound shows a good transfer into the blood and a long blood half-life in the blood kinetic test using a guinea pig orally administered with the compound and is stable in an animal plasma. The compound also shows a high transfer to the central nervous system when it is orally administered to a guinea pig at a certain dose. Accordingly, the benzyloxypropylamine derivative is quite useful as a novel anti-tachykinin agent. | 10-23-2008 |
